About Us

Our Vision

Thrombotech is dedicated to bringing fundamental improvement to the current treatment for stroke in order to save millions of patients from death and disability. Thrombotech researchers are committed to identifying the basic problems impeding treatment within the currently used methods and medications, and shall continue to create innovative solutions that will soon make the current inability to effectively treat the vast majority of embolic stroke patients a thing of the past.
We believe we can realize our vision through the scientific advancement of our innovation, the short synthetic peptide THR-18, whose performance to date has shown great potential.

“If these results are extended to humans, they could usher in a new era of thrombolytic therapy for stroke, which is the leading cause of disability in the world and the third leading cause of death in the United States after cancer and heart disease”

Johns Hopkins neurologists Ted M Dawson and Valina L Dawson, in the Volume 12 2006 issue of Nature Medicine.

Design By Ruth Kenan, Site by Imaginet